Attenuated Hepatitis A Vaccine, H2 Strain
Biological6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
NCT Number: NCT02601040
The main purpose of this study was to evaluate the safety and immunogenicity of Immunogenicity of Inactivated and Live Attenuated Hepatitis A Vaccines for healthy Chinese people.
Looking for future studies?
Notify Me18 month–65 year
All sexes
Interventional
Phase 4
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
Time frame: 37 months
Changes of anti Hepatitis A antibody geometric mean concentrations at pre-vaccination, month 1,12, 24, 36, and 1 months after the booster vaccination.
Time frame: 28 days
Compare incidence of all the solicited events(AEs), unsolicited AEs and serious AEs within 28 days post-vaccination.
Jiangsu Province Centers for Disease Control and Prevention
Network
Phase IV Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine in Health Chinese Children and Adult
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06576024
Blood-Borne Infections, Communicable Diseases
Liuzhou, Guangxi, China
View Trial DetailsNCT06298708
Digestive System Diseases, Enterovirus Infections
Chiang Mai, Thailand
View Trial DetailsNCT03312699
Bacterial Infections, Bacterial Infections and Mycoses
Stanford, California, United States
View Trial DetailsNCT00139113
Digestive System Diseases, Enterovirus Infections
Anchorage, Alaska, United States
View Trial Details